trending Market Intelligence /marketintelligence/en/news-insights/trending/Ei5WH0Dct2eWC9GiMiKEEQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sanofi recalls over-the-counter Zantac in US, Canada due to possible impurity

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Sanofi recalls over-the-counter Zantac in US, Canada due to possible impurity

Sanofi is voluntarily recalling its over-the-counter heartburn medication Zantac in the U.S. and Canada, as a precaution against possible presence of an impurity called N-nitrosodimethylamine, or NDMA.

Paris-based Sanofi said it will determine the scope of the recall with the relevant health agencies, according to its Oct. 18 press release.

Sanofi is the latest in a line of drugmakers to pull Zantac off shelves after the U.S. Food and Drug Administration, Health Canada and the European Medicines Agency warned in September that the over-the-counter drugs, also available as generic ranitidine drugs, may contain NDMA, which is said to be a cancer-causing chemical.

Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Mylan NV and Novartis AG have already recalled their generic ranitidine medicines.

NDMA was also found in batches of another heart medication known as sartan drugs in 2018, spurring global recalls and regulatory investigations of the contamination.